Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | VNN1 | O95497 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12864485 | 0.83 | EPHX2 (0.59) | EPHX2NR1H4 | |
| SCHEMBL5321683 | 0.78 | BACE1 (0.73) | SMN1; SMN2DGAT2KMT2AMEN1 | |
| SCHEMBL5321691 | 0.78 | BACE1 (0.73) | SMN1; SMN2DGAT2KMT2AMEN1 | |
| SCHEMBL27859550 | 0.77 | EPHX2 (0.62) | SMN1; SMN2EPHX2NR1H4VNN1 | |
| SCHEMBL12757447 | 0.76 | ALDH1A1 (0.62) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29183458 | 0.76 | EPHX2 (0.54) | SMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL4575623 | 0.75 | BCHE (0.50) | GAAALDH1A1KMT2AVNN1MEN1 | |
| SCHEMBL3966634 | 0.75 | EPHX2 (0.63) | ALDH1A1RAB9ASMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL29699722 | 0.75 | ALDH1A1 (0.60) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12809804 | 0.75 | ALDH1A1 (0.55) | GAAALDH1A1EPHX2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | GAA 427/4885ALDH1A1 645/4885NPC1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.